​We are excited to announce that Visikol has been acquired by BICO (formerly CELLINK). A FVCG company since 2016, Visikol was founded by Michael Johnson and Tom Villani.
With this acquisition, Visikol hopes to accelerate its growth and expand its portfolio of companies for which it provides advanced imaging and advanced cell culture assay services. 



We welcome NemaGen to the portfolio of companies in which FVCG has invested. Founded by Mark C. Siracusa, PhD, Assistant Professor at Rutgers New Jersey Medical School, NemaGen is focused on advancing therapies to prevent allergic inflammation and mast-cell related diseases.

We look forward to working together to help advance NemaGen's discoveries with exciting therapeutic potential.


Congratulations to Kayothera, Inc. (a Foundation Venture Capital Group portfolio company), the BIO 2021 Start-up Stadium Winner!